On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Viking Therapeutics (NASDAQ:VKTX). "This is a really fine company, and it will do well for multiple years because they have many ships coming in," he added.
On Sept. 11, JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65.
Gentex Corporation (NASDAQ:GNTX) is "too closely related to autos, and autos have been hurt so bad. And I don't see a quick turn. We're going to need several Fed rate cuts before they turn," Cramer said.
On July 26, the company reported second-quarter earnings per share of 37 cents, but it missed the street view of 52 cents. Quarterly sales of $572.93 million missed the analyst consensus of $622.79 million.
The Mad Money host said Cadre Holdings, Inc. (NYSE:CDRE) is a "good simple story."
On Aug. 9, Cadre Hldgs reported quarterly earnings of 31 cents per share which beat the analyst consensus estimate of 27 cents per share. The company reported quarterly sales of $144.31 million which beat the analyst consensus estimate of $142.05 million.
"Something's the matter with Celsius Holdings, Inc. (NASDAQ:CELH)," Cramer said. "I want to know what's wrong."
On Sept. 19, Celsius Holdings appointed Hans Melotte to the company's Board of Directors.
Price Action:
- Viking shares gained 5.8% to settle at $68.16 on Thursday.
- Gentex shares gained 1.8% to close at $29.82 during the session.
- Cadre shares gained 2.4% to close at $37.36 during Thursday's session.
- Celsius shares fell 0.6% to settle at $34.07 on Thursday.
- Coinbase Global, Electronic Arts And 2 Other Stocks Executives Are Selling